BIO-PATH HOLDINGS, INC. (BPTH): Nasdaq/NYSE listing notice — Bio-Path receives Nasdaq deficiency notice for bid price below $1.00

BIO-PATH HOLDINGS, INC.

Nasdaq notified Bio-Path that closing bid price was below $1.00 for 30 consecutive business days.
Company has 180 days, until March 11, 2024, to regain compliance by having bid price ≥ $1.00 for ten consecutive days.
If not compliant by March 11, 2024, may seek a second 180-day cure period if eligible.
Company may consider a reverse stock split to remedy the bid price deficiency.
Listing on Nasdaq Capital Market under symbol BPTH is unaffected during cure period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIO-PATH HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 13, 2023, Bio-Path Holdings, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar da

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-015818

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.